Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
about
Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Expert opinion on the treatment of patients with chronic hepatitis CA Multi-Step Process of Viral Adaptation to a Mutagenic Nucleoside Analogue by Modulation of Transition Types Leads to Extinction-EscapeMutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing MutationsCoronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeuticsRetreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.Hematologic disorders associated with hepatitis C virus infection and their management.Triple antiviral therapy in HCV positive patients who failed prior combination therapyInterferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Management issues in chronic viral hepatitis: hepatitis C.Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B.Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.Retreatment of patients with chronic hepatitis C.Treatment of chronic hepatitis C: a systematic review.Polyethylene glycol-interferon: current status in hepatitis C virus therapy.Challenges for the development of ribonucleoside analogues as inducers of error catastrophe.Therapeutic modalities in hepatitis C: challenges and development.Retreatment of chronic hepatitis C in previous non-responders and relapsers.A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan.Therapeutically targeting RNA viruses via lethal mutagenesis.De novo initiation pocket mutations have multiple effects on hepatitis C virus RNA-dependent RNA polymerase activities.Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.Ribavirin can be mutagenic for arenaviruses.5'-nor carbocyclic ribavirin.Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antRacial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients.A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.Tropolone and its derivatives as inhibitors of the helicase activity of hepatitis C virus nucleotide triphosphatase/helicase.High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses.Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.Treatment and retreatment in patients with chronic hepatitis C: 10 years clinical practice in a single centre.
P2860
Q24805127-C6EF0FBF-2D73-43E8-BD69-348E79EA2156Q27489903-42442F48-A628-41EE-B5EE-BC3AD9FCDBCBQ27664656-5E9E5E39-F1F7-4BC8-A17B-FAF99418BB50Q28072953-B1D6E580-1082-46E7-8A5F-A0BF6BB32757Q28535361-C80BD06D-872F-402C-B7FB-40A7BC40655FQ30746310-6C92AB6D-DAC0-4A26-AAE7-60CD621204D2Q33349378-3AF4CC43-A7AC-42E3-8F9F-4F6E513F5282Q33869358-32C346F7-6088-4EB7-835A-846855A278C2Q33947375-5FE5AB3D-92F8-49B6-9A3C-44CDBF9F89AFQ34619371-6726F8C2-7696-43C4-8493-A29278ACDB4FQ34694495-C530A6BF-C87B-4CFE-96B1-56343C943A43Q34799386-12466C62-C8A9-4EDF-8E2C-922A364D1F02Q34799396-FB9CAE7B-3F74-4B54-93AA-BFB9AF6967A2Q34984083-6CC5069B-C87F-4597-A861-9A6EB4E782F1Q34984085-72815648-51E8-4434-B5EF-C7904E67FE13Q35020845-9B40E8D2-C283-4B9B-8B19-8385F03EBE5FQ35742174-4ECC6248-4039-4A86-86A1-9A3C29ABF49AQ36011951-D9027EDE-457D-4869-9D0F-982D0FF9156DQ36968144-B3CCD0F4-BEBD-44EA-992B-784A116F20A9Q37356788-32A8A871-9A4F-4964-B8E5-47E2B2C17001Q37591219-E53D97FE-07BD-4770-96D8-469719E36E54Q37596636-9C291AC0-A002-40DA-86DB-7CA1903B9037Q38966123-328BC570-2DDD-4B2F-874A-EF5A986B1E3DQ39157496-5019B8F4-D2AB-43E4-86E1-77A615F05196Q39544616-B5FCAAE2-2DE2-4F32-B7F1-ABE461C10EA8Q40543749-B648BFF8-A0C0-488E-91FA-931FCF26F4B2Q40902801-2D46589C-8653-4B08-B6F5-C3031424DDE9Q41528192-DF183E55-A057-4945-9F56-186130064F4FQ42502604-7BC44837-CA36-49B7-B028-203CC0C18873Q42987414-0DA112FB-0006-4FA8-8770-2E127A6030B9Q42988399-FD46E71A-8FC8-4B48-9D19-C28F722B0AEDQ42996520-3F5EE3A0-79F0-48AB-8699-E752E3602243Q42999278-D5765A94-60E2-4DA9-BCFE-99B93A77B8D5Q43038148-3C98BC5B-F48F-4456-8624-BBA7ADCCD0E4Q43041197-89DDD3EF-D43B-4DD4-8A26-FAA9F6493154Q43048560-848E373B-52F5-46DB-B851-BAAB450CAC90Q43048856-3AA6A872-6D1F-4128-8EEA-04BD75B9591EQ44115945-0F94DFFB-864D-4A2C-8318-E9CBBEB5E482Q50550986-A9653272-0EBC-4A1E-A08A-C0A5EC7C80CBQ50573828-ED68CD09-DBCE-4FE7-983C-6258E288BC0A
P2860
Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interferon and ribavirin vs in ...... analysis of randomized trials.
@ast
Interferon and ribavirin vs in ...... analysis of randomized trials.
@en
Interferon and ribavirin vs in ...... analysis of randomized trials.
@nl
type
label
Interferon and ribavirin vs in ...... analysis of randomized trials.
@ast
Interferon and ribavirin vs in ...... analysis of randomized trials.
@en
Interferon and ribavirin vs in ...... analysis of randomized trials.
@nl
prefLabel
Interferon and ribavirin vs in ...... analysis of randomized trials.
@ast
Interferon and ribavirin vs in ...... analysis of randomized trials.
@en
Interferon and ribavirin vs in ...... analysis of randomized trials.
@nl
P2093
P356
P1476
Interferon and ribavirin vs in ...... analysis of randomized trials.
@en
P2093
J Cid-Ruzafa
K J Cummings
M S Sulkowski
S N Goodman
P304
P356
10.1001/JAMA.285.2.193
P407
P577
2001-01-01T00:00:00Z